GHRS
GH Research PLCHealthcare·Biotechnology
$23.99
$1.6B market cap
Revenue
$0.0M
Free Cash Flow
$-23.0M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The compan
2-Year Price History
$22.12+83.3%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q1 | 0.0 | -18.7 | -18.8 | -19.0 | -10.7 | -10.7 | -0.1 | 267.3 | 0.4 | 62.0 | -101.9% | -222.1x | -- |
| Act | 2025-Q4 | 0.0 | -16.6 | -16.7 | -14.1 | -12.3 | -12.3 | -0.0 | 280.7 | 0.5 | 62.0 | -73.1% | -184.6x | -- |
Valuation & Metrics
Market Stats
Price$23.99
Market Cap$1.6B
Enterprise Value$1.4B
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-1.4%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-33.1M
Free Cash Flow$-23.0M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-87.5%
WC Change % Rev0.0%
Interest Coverage-202.7x
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.2M
Days to Cover5.9
Change (vs Prior)-0.2%
Need at least 2 settlement dates for chart
Employees
Headcount50
Revenue / Employee$0
Gross Profit / Employee$-3,580
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
44.1%(+12.8% YoY)
48 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
0.5%(+0.4% YoY)
4 filers
Vanguard, iShares, SPDR
Market makers
0.0%(+0.0% YoY)
1 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| Lynx1 Capital Management LP | $151M | $11.36 | +$5.0M | +$60.7M | +3.3% | $633M |
| BVF INC/IL | $122M | $5.80 | −$2.5M | −$2.5M | -0.3% | $3.14B |
| RA CAPITAL MANAGEMENT, L.P. | $108M | $10.44 | +$0 | +$10.3M | -4.4% | $9.44B |
| RTW INVESTMENTS, LP | $83.4M | $10.93 | +$0 | +$6.1M | -2.2% | $9.26B |
| FMR LLC | $72.2M | $11.64 | +$0 | +$12.5M | -0.0% | $1.89T |
| Avoro Capital Advisors LLC | $25.3M | $12.70 | +$0 | +$25.3M | +1.3% | $10.15B |
| TORONTO DOMINION BANK | $19.7M | $11.03 | −$8.0M | −$8.0M | -0.3% | $51.72B |
| Troluce Capital Advisors LLC | $13.9M | $13.23 | +$8.7M | +$11.7M | +0.8% | $945M |
| MILLENNIUM MANAGEMENT LLC | $13.2M | $13.59 | +$9.0M | +$13.2M | -0.5% | $127.40B |
| Jefferies Financial Group Inc. | $10.0M | $11.04 | +$0 | −$530K | -1.6% | $7.90B |
| 5AM Venture Management, LLC | $8.1M | $10.71 | +$0 | +$0 | +0.9% | $360M |
| BlackRock, Inc.Passive | $6.4M | $11.93 | +$298K | +$5.8M | -0.2% | $5.69T |
| UBS Group AG | $5.8M | $11.47 | +$689K | −$499K | -0.3% | $562.11B |
| Squadron Capital Management LLC | $4.6M | $12.74 | +$141K | +$4.6M | +17.8% | $250M |
| Foresite Capital Management VI LLC | $4.4M | $14.06 | +$4.4M | +$4.4M | +9.4% | $460M |
| BOOTHBAY FUND MANAGEMENT, LLC | $4.0M | $13.68 | +$2.4M | +$3.6M | -0.4% | $4.25B |
| CenterBook Partners LP | $3.0M | $13.64 | −$940K | +$3.0M | -0.3% | $1.85B |
| HighVista Strategies LLC | $3.0M | $13.88 | −$384K | +$3.0M | +2.4% | $358M |
| MARSHALL WACE, LLP | $1.3M | $13.83 | −$2.1M | +$1.3M | +0.6% | $92.71B |
| Occam Crest Management LP | $1.1M | $14.06 | +$1.1M | +$1.1M | -3.7% | $158M |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.17%
avg per quarter
Holders (ex-self)
-0.09%
excl. this stock
Buyers (this Q)
+2.15%
26 buyers · $0.05B in
Sellers (this Q)
-2.42%
17 sellers · $-0.00B out
alpha coverage: 100% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-5.5%
how holders react when this stock falls
On quiet Qs
+20.0%
−10% to +10% baseline
On rallies (+10%+)
+4.5%
how they react when this stock rises
Holders' portfolio flow this Q
+15.5%
inflows — adds are organic
Sellers' portfolio flow this Q
+15.6%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-0.9%
Holder mid (any stock)
-3.6%
Holder rally (any stock)
+2.3%
Biggest decreases this quarter
Cormorant Asset Management, LLCexited−$16.5MVerition Fund Management LLCexited−$8.6MTORONTO DOMINION BANK−$8.0Mα-0.3Alyeska Investment Group, L.P.exited−$2.6MBVF INC/IL−$2.5Mα-0.3MARSHALL WACE, LLP−$2.1Mα+0.6CenterBook Partners LP−$940Kα-0.3JANE STREET GROUP, LLCexited−$635KBIT Capital GmbHexited−$635KGOLDMAN SACHS GROUP INC−$509Kα-0.2
New buyers this quarter
Top-5 holders · 80.3%
Lynx1 Capital Management LP--
BVF INC/IL--
RA CAPITAL MANAGEMENT, L.P.--
RTW INVESTMENTS, LP--
FMR LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
BVF INC/IL8.7MLynx1 Capital Management LP10.8MFMR LLC5.1MRA CAPITAL MANAGEMENT, L.P.7.7MRTW INVESTMENTS, LP5.9MVR Adviser, LLC—ORBIMED ADVISORS LLC—CITADEL ADVISORS LLC65KVerition Fund Management LLC—Cormorant Asset Management, LLC—
Related Stocks
Investors who own this also own
Stocks held by the same active managers as this one, ranked by score — how much more often these appear together than random chance (1× = baseline). Excludes index ETFs and market makers; minimum 3 shared holders.
| Ticker | Name | Co-holders | Score |
|---|---|---|---|
| TYRA | Tyra Biosciences, Inc. | 3 | 227.57× |
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (4 analysts)$41.507300.0%
Last Year (11 analysts)$36.005010.0%
Current Price$23.99
Analyst Ratings
9
Buy: 9Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
11.8%retail-15.5pp
31.6%dark+8.4pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
GH Research PLC: Massive Executive Option Windfall Masked by Clinical Cash Burn
Overall Risk
4/10
Fraud
2/10
Dilution
7/10
Insolvency
2/10
Earnings Overstated
3/10
Hidden Liabilities
2/10
Legal
3/10
Audit Warnings
3/10
Hidden Upside
6/10
Contextually Acceptable
8/10